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Abstract
BACKGROUND: Diabetes mellitus was associated with hypoxia condition and result ischemia and induced 
neovascularization and other forms of the cell adaptation in response to the tissue concentrations of low oxygen 
levels. Hypoxia-Inducible Factor 1 alpha a marker of the cell adaptation as a hypoxic cell response which was due 
of chronic hiperglycemia.
AIM: The aim of this study to know the relationship between Hba1c and plasma HIF-1 α level at type 2 diabetes 
mellitus patients.
METHODS: The cross-sectional study design using the 89 samples of diabetes mellitus patients who attended 
Murni Teguh Hospital in Medan of Indonesia country. The inclusion criteria of the samples were all the patients 
diagnosed with type 2 diabetes mellitus both the sexes. Body mass index, blood pressure, and disease history six 
socioeconomic status was recorded. The laboratory parameters, including fasting blood sugar and Hba1c were 
examined by Murni Teguh Hospital Laboratory.
RESULTS: The result of the study we found that there was no significant difference the hypoxia-inducible factor 1α 
level (HIF-1α) at type 2 diabetes mellitus with malignancy was higher compared at type 2 diabetes mellitus without 
malignancy.
CONCLUSION: The patient’s type 2 diabetes mellitus with the high HIF-1α levels have a poor prognosis compared 
with the lower levels because the high HIF-1α will tend to have a risk complication of malignancy or the other 
complication of diabetes mellitus.
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Introduction
Diabetes mellitus (DM) is a progressive 
chronic disease caused by years of insulin resistance 
and hyperinsulinemia before the development of 
hyperglycemia. Previously, the prediabetes phase 
could have been more than 10 years before being 
diagnosed with Type 2 diabetes mellitus, where this 
phase is often referred to as a metabolic syndrome, 
where this condition is always compared to abdominal 
obesity, failure of glucose tolerance, dyslipidemia, and 
hypertension [1]. Reliable, fasting blood sugar level 
was measured by measuring hemoglobin glycosylate 
concentration (HbA1C). HbA1C was specific 
hemoglobin with the glucose that binds to free amino 
acid groups formed from non-enzymatic reactions by 
hemoglobin which are exposed to high glucose levels 
in the plasma. The relationship between HbA1C and 
glucose in blood plasma is very complex. Routinely 
HbA1c is used as a diagnostic tool to measure glucose 
levels in the blood and can be used to predict the risk of 
developing complications in DM patients [2].
Diabetes mellitus is often associated with a 
state of hypoxia and results in ischemia which induced 
neovascularization and other forms of the cell adaptation 
in response to tissue concentrations of low oxygen 
levels. The cell adaptation response to hypoxia is 
relaxed by a marker called hypoxia-induction factor-1α 
(HIF-1α), where a condition that changes hyperglycemia 
becomes a loss of cellular response to hypoxia in 
most complications of diabetes. Hypoxia interacts with 
hyperglycemia resulting in complications [3]. Hypoxia-
inducible factor-1α (HIF-1α) was a critical transcription 
factor involved in oxygen homeostasis that regulates 
various adaptive responses to hypoxia, including 
angiogenesis, metabolic processes, and survival. 
Thus, the destabilization of HIF-1 tends to hurt the 
cell and tissue adaptation to low oxygen [4], [5]. Both 
hyperglycemia and hypoxia were important features 
of diabetes complications and appear to cause some 
adverse effects, which lead to complications such as 
diabetic retinopathy, poor wound healing, neuropathy, 
cardiovascular disease, and kidney [6]. In normoxic 
conditions, HIF1α is degraded and this process is 
oxygen-dependent [7]. Hyperglycemia regulates the 
stability and function of HIF-1α [8].
In the previous study, there was a relationship 
between HIF-1α and type 2 diabetes mellitus and 
patients with hyperglycemia showed elevated levels 
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of HIF-1α [9]. Moreover, the research conducted in 
patients with diabetes mellitus with retinopathy found 
an increase in levels of HIF-1 α compared with type 
2 diabetes mellitus without retinopathy [10]. Recently, 
a study showed that serum HIF-1α in diabetic patients 
with breast cancer significantly higher than in the 
normal population [11]. Because of many, the previous 
studies have found a significant relationship between 
increasing levels of the HIF-1α with type 2 diabetes 
mellitus, also the relationship with malignancy so that in 
this research we aimed to determine how is the HIF-1α 
level at type 2 diabetes mellitus with malignancy and 
without malignancy who attend to Murni Teguh Hospital 
in Medan city, North Sumatera, Indonesia.
Materials and Methods
Subjects
We included 89 (average age 58.22 ± 9.051 
years, 40.4% men and 59.6% female) consecutive 
type 2 diabetes mellitus with malignancy and type 2 
diabetes mellitus without malignancy, between January 
and July 2019, who came to Murni Teguh Hospital in 
Medan, North Sumatera, Indonesia, according to ADA 
and WHO guidelines. The samples were composed of 
all type 2 diabetes mellitus with or without malignancy 
both male and female, without exception the age and 
treatment. The exclusion criteria were type 1 diabetes 
mellitus. Physical examinations were performed to 
record patient demographics, including height, weight, 
body mass index (BMI), and blood pressure. All 
participants were provided written informed consent at 
the visits. This study complied with the Declaration of 
Helsinki. Our study was approved by our institutional 
Health Research Ethics Committee with number 484/
TGL/KEPK FK USU-RSUP HAM 2019.
Biochemical measurements
Blood samples were collected from subjects 
at a visit to the outpatient clinic after an overnight fast. 
The samples were centrifuged at 3000 rpm at 4°C for 
15 min. The supernatants were decanted and frozen 
at −80°C until assayed. Fasting blood sugar (FBS) 
and Hba1c were measured using standard methods. 
Enzyme-linked immunosorbent assay (ELISA) 
kits were used to measure serum levels of HIF-1α 
(Cayman Chemical Co, Ann Arbor, Michigan, USA). 
The plate has been pre-coated with the human HIF-1 
α antibody. HIF-1α present in the sample is added 
and binds to antibodies coated on the wells. And then 
biotinylated human HIF-1α. The antibody is added and 
binds to HIF-1α in the sample. The substrate solution 
is then added and color develops in proportion to the 
amount of human HIF-1α. The reaction is terminated 
by the addition of acidic stop solution and absorbance.
is measured at 450 nm. Intra-assay and inter-assay 
coefficients of variation for HIF-1α were < 8% and 
<10%, respectively.
Statistical analysis
Statistical analysis SPSS version 24.0 (SPSS 
Inc, Chicago, Illinois) statistical software was used for 
statistical analysis. We used the Shapiro–Wilk normality 
test. Continuous variables in normal distribution were 
compared using the Student’s t-test. To assess the value 
of serum HIF-1α, we used nonparametric analysis.
Results and Discussion
A total of 89 consecutive samples in this 
research that 36 samples (40.4%) were man and 53 
samples (59.6%) were female. In this research, the 
minimum age of the samples was 37 years and a 
maximum of the age was 77 years, where the mean 
age of the samples was 58.22 ± 9.05 years old. We 
have a minimum body mass index (BMI) of the samples 
were18.55 and a maximum of BMI was 21.84 kg/m2 
and the mean of the BMI was 25.38 ± 4.57 kg/m2. The 
minimum of the Fasting blood sugar levels (FBS) of the 
sample 83 mg/dL and a maximum of 635 mg/dL, where 
the mean of FBS was 243.55 ± 97.664 mg/dL.
In this study that we found that the mean of the 
fasting blood sugar level (FBS) at the patients in type 2 
diabetes mellitus with malignancy 260.45 ± 16.69 mg/dL 
and without malignancy 89.46 ± 12.78 mg/dL, the mean 
of Hba1c value of the diabetes mellitus with malignancy 
patients 7.573 ± 0.357% and the mean of Hba1c value 
of the diabetes mellitus without malignancy patients 
9.34 ± 0.232%, the mean of the HIF-1α of the diabetes 
mellitus with malignancy patients 1.67 ± 0.59 ng/ml, 
and the mean of the HIF-1α of the without malignancy 
0.69 ± 0.12 ng/ml (Table 1).
In our study, using statistics, we found that 
there was no difference significantly HIF-1α at type 2 
diabetes mellitus with malignancy and type 2 diabetes 
mellitus without malignancy (p > 0.0005). Diabetes 
mellitus is characterized by defects in hypoxia-induced 
neovascularization in the myocardium, skeletal muscle, 
nerves, and skin [12]. In this study, we found of the 
samples that the HIF-1α level at type 2 diabetes mellitus 
with malignancy patients was higher than without 
malignancy. As we know that HIF-1α was a major factor 
to regulate oxygen homeostasis and plays a key role 
in many physiologic and pathology processes [13] and 
hyperglycemia regulates HIF-1α protein stability and 
functions, destabilizing it, ultimately resulting in poor cell 
and tissue responses to hypoxia [14]. In this research 
that fasting blood sugar (FBS) at both of the samples, 
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the mean was above the normal value. Moreover, this 
research, there was a significant difference between 
Hba1c at type 2 diabetes mellitus with malignancy and 
without malignancy (p < 0.0005).
In this cross-sectional study in type 2 diabetes 
mellitus subjects, we first evaluated the fasting blood 
sugar and Hba1c, and then we evaluated the HIF-1α 
level. Previous studies have clarified the relationship 
between HIF-1α and diabetes. Jiang et al. found that 
inhibition of HIF-1 in adipose tissue ameliorates obesity 
and insulin resistance [15]. The other research by Li et al. 
with coronary artery calcification in asymptomatic type 
2 diabetic patients showed that a significantly increased 
in serum HIF-1 α level [16]. This may be caused not only 
by myocardial anoxia reflex but also due to hypoxic levels 
in the local tissue. Research by Catrina et al. reports that 
hyperglycemia impairs hypoxia-dependent stabilization 
of HIF-1α, where the research suggests a mechanism 
of cross-coupling between two of the most important 
determinants of the chronic complications in diabetes 
mellitus hyperglycemia and hypoxia [7]. This research 
no significant difference HIF-1α at type 2 diabetes 
mellitus with malignancy and type 2 diabetes mellitus 
without malignancy. Hypoxia has a prominent effect 
on all diabetic complications. Hyperglycemia regulates 
HIF-1α protein stability and functions, destabilizing it, 
ultimately resulting in poor cell and tissue responses to 
hypoxia. Hypoxia may interact with hyperglycemia and 
promote diabetes and its complications [15]. Adaptive 
responses of cells to hypoxia are mediated by hypoxia-
inducible factor-1 (HIF-1), in particular, by HIF-1α. 
Research has shown that increased angiogenesis is 
closely associated with the HIF-1α pathway, and the 
HIF-1α axis plays a pivotal role in malignancy [17]. In 
this research, there was no significant difference HIF-1α 
at type 2 diabetes mellitus with and without malignancy. 
The mean of HIF-1 α at type 2 diabetes mellitus with 
malignancy 1.67 ng/ml and type 2 diabetes mellitus 
without malignancy 0.69 ng/ml (Table 2). As we know that 
the diabetes mellitus disease relationship with hypoxia 
and hypoxia interacts with hyperglycemia resulting in 
Table 1: Characteristic of the samples
Characteristic of the samples
n Minimum Maximum Mean Standard deviation
Age 89 37 77 58.22 9.051
BMI 89 18.55 41.84 25.3825 4.57065
FBS 89 83 635 243.55 97.664
Hba1c 89 2.4 14.0 8.545 2.1146
HIF-1α 89 0.00 17.80 1.1283 2.60571
Valid N (listwise) 89
complications and malignancy, the complication of 
type 2 diabetes mellitus occurs hypoxia process; this 
is due to the limited oxygen supply during the process 
of rapid anabolic cell proliferation. Hence, the samples 
in this research both type 2 diabetes mellitus with or 
without malignancy found that hypoxia area. This study 
used samples with all types of malignancies and does 
not classify types of samples with certain malignancies, 
then also does not classify samples that have received 
anticancer therapy and have not received therapy with 
anti-cancer.
Conclusion
Although in this study we found that there 
was no significant difference HIF-1α at type 2 diabetes 
mellitus with malignancy and without malignancy, the 
patients type 2 diabetes mellitus with the high HIF-1α 
levels have a poor prognosis compared with the lower 
levels because the high HIF-1α will tend to have a risk 
complication of malignancy or the other complication of 
diabetes mellitus.
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